MedTrace Logo

Brigham and Women's Rheumatoid Arthritis Sequential Study

NCT01793103 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1598

Last updated 2025-09-26

No results posted yet for this study

Summary

The goal of the present study is to establish a prospective observational cohort of Rheumatoid Arthritis patients in order to

1. Determine and validate biomarkers that predict drug response and toxicity in RA.
2. Determine and validate biomarkers that predict disease activity and prognosis in RA.
3. Evaluate the natural history of treated RA in terms of its clinical, functional and economic outcomes.

Conditions

Sponsors & Collaborators

  • Crescendo Bioscience

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • UCB Pharma

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Janssen, LP

    collaborator INDUSTRY

  • Aqtual, Inc.

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Nancy A Shadick, MD, MPH · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793103 on ClinicalTrials.gov